|
|
|
 |
S. J. Enna
Dr. S. J. Enna received his B.A. degree from Rockhurst University, Kansas City, Missouri and both his M.S. and Ph.D. degrees from the University of Missouri-Kansas City. Postdoctoral training in pharmacology was completed at the University of Texas Southwestern Medical School in Dallas, at F. Hoffmann‑La Roche in Basel, Switzerland, and the Department of Pharmacology and Experimental Therapeutics at Johns Hopkins University School of Medicine in Baltimore. Dr. Enna spent 10 years on the faculty at the University of Texas Medical School at Houston in the Departments of Pharmacology and Neurobiology. While at the University of Texas Dr. Enna was also a consultant for ICI‑USA, Inc., Merck, Sharp and Dohme Research Laboratories, Bristol‑Myers Corporation, and Panlabs, Inc. From 1986‑1990, Dr. Enna was Senior Vice President and Scientific Director of Nova Pharmaceutical Corporation in Baltimore, and Executive Vice President from 1990‑1992. He is currently Associate Dean for Research and Graduate Education as well as Professor of Physiology and of Pharmacology at the University of Kansas Medical School. Dr. Enna served as chair of the Department of Pharmacology, Toxicology and Therapeutics at the University of Kansas Medical School from 1992 to 2003. Other previous academic appointments include Lecturer in the Department of Neuroscience at The Johns Hopkins University School of Medicine in Baltimore and Adjunct Professor of Pharmacology at Tulane University School of Medicine in New Orleans.
Dr. Enna served for six years as editor of The Journal of Pharmacology and Experimental Therapeutics, and is currently co-editor of Current Protocols in Pharmacology and of xPharm, an on-line pharmacology reference work. He is also Editor-in-Chief of Biochemical Pharmacology and Executive Editor-in-Chief of Pharmacology and Therapeutics. Besides his editorships, Dr. Enna serves on the editorial boards of Brain Research, Life Sciences and CNS Drug Reviews. He has been the recipient of Research Career Development Awards from the National Institute of Mental Health and the National Institute for Neurological, Communicative Disorders and Stoke. Other awards include the John Jacob Abel Award from the American Society for Pharmacology and Experimental Therapeutics, the Daniel H. Efron Award from the American College of Neuropsychopharmacology, and a PhARMA Foundation Excellence Award. In recent years he has been a member of the Scientific Advisory Council of Abbott Laboratories and has served on the Board of Directors of the Life Sciences Research Office.
Among his current appointments is membership on the Scientific Advisory Board of the National Alliance for Autism Research, and on the Basic Pharmacology Advisory Committee of the PhARMA Foundation. Dr. Enna has held many elective offices in professional societies including the presidency of the American Society for Pharmacology and Experimental Therapeutics (ASPET). He is currently Secretary General of the International Union of Basic and Clinical Pharmacology (IUPHAR).
Dr. Enna's research interests include neuropharmacology, neurochemistry and neuropsychiatric disorders. He has made significant contributions in defining the pharmacological and biochemical properties of neurotransmitter receptors, in particular those for GABA. He has also conducted research into the effects of hormones on neurotransmitter receptor function and receptor responses to psychotherapeutics, the development of receptor antagonists for NMDA, cholinergic muscarinic and bradykinin receptors, and the identification of the cellular components of coincident signaling in brain. Dr. Enna's research is described in over 200 published research reports, reviews, and book chapters. He has edited two dozen books on topics ranging from neuropharmacology in general, to neurotransmitter receptors and GABA.
|
 |
Michael Williams
Michael Williams, Ph.D., D.Sc. has worked for over 30 years in the US-based pharmaceutical industry and is currently Vice President of Worldwide Discovery Research at Cephalon, Inc., in West Chester, Pennsylvania. Dr. Williams received his Ph.D. (1974) from the Institute of Psychiatry and his Doctor of Science degree in Pharmacology (1987), both from the University of London. He is a Fellow of the American Association for the Advancement of Science (AAAS) and a member of the American Society for Pharmacology and Experimental Therapeutics (ASPET), the American College of Neuropsychopharmacology (ACNP), the Collegium Internationale Neuro-Psychopharmacologium (CINP) and the International Association for the Study of Pain (IASP). Dr. Williams is Adjunct Professor in the Department of Molecular Pharmacology and Biological Chemistry at the Feinberg School of Medicine, Northwestern University, Chicago, Illinois and is the author/co-author of more than 300 research publications, book chapters and reviews and has edited nine monographs.
|
 |
James L. Ellis, Ph.D.
Dr. Ellis has 20 years of biopharmaceutical and academic experience. Dr. Ellis joined Sirtris Pharmaceuticals in November 2008 as Vice President, Preclinical Research where he is responsible for the Target Discovery, Pharmacology and Safety/Toxicology groups. Prior to Sirtris Pharmaceuticals, Dr. Ellis was Vice President of Research at Surface Logix responsible for the management of the company's internal and external research efforts in metabolic disease, cardiovascular disease, inflammation and oncology. Prior to joining Surface Logix, Dr. Ellis held the position of Executive Project Director & Chief Biology Advisor at NitroMed Inc. in Lexington, MA. In this role Dr. Ellis was responsible for managing NitroMed's biology group in support of various drug discovery programs in the areas of cardiovascular disease and chronic inflammation. Prior to joining NitroMed, Dr Ellis was Senior Director, Pharmacology and Global Leader for Allergy & Respiratory Disease for UCB Pharma, Cambridge MA. Dr. Ellis was an Assistant Professor of Medicine at Johns Hopkins University in Baltimore, MD from 1992-1996. Dr. Ellis has a Ph.D. in Neurobiology from the University of London, a BSc. in Pharmacology from the University of Aberdeen, Scotland and he carried out postdoctoral work at the Johns Hopkins Asthma & Allergy Center.
|
 |
John Ferkany
Prior to joining Surface Logix, Dr. Ferkany served as Senior Vice President for Virtual Drug Development Incorporated, a privately held biotechnology company engaged in developing therapeutic strategies for biodefense. Dr. Ferkany has also served as Vice President and Chief Technical Officer of NovaScreen BioSciences Corporation, an international contract research organization providing screening, profiling and assay development services for pharmaceutical and biotechnology companies worldwide, and for government agencies including the National Institutes of Health. He also headed his own consulting firm focused on regulatory preclinical drug development. He also led the Central Nervous Research group at Nova Pharmaceutical Corporation, the first successful biotechnology spin-out from the Johns Hopkins University .
From: http://www.surfacelogix.com/news/news_051010.htm
Dr. Ferkany's educational background includes a B.S. in Zoology (1976) from the University of Michigan, a doctoral degree in Biomedical Sciences (1980) from the University of Texas at Houston, and a Masters in Administrative Sciences (1991) awarded from the Johns Hopkins University in Baltimore, Maryland where the incumbent received the Edward J. Stegman Award for Excellence having graduated with a perfect record.
Dr. Ferkany is a member of the editorial board of the Journal of Pharmacology and Experimental Therapeutics and of Current Protocols in Pharmacology, of 4 scientific Societies, and has published extensively in the field of central nervous system disorders as well as on current methods in drug discovery. He is a consensus manager dedicated to team concepts, "coaching" and the advancement of subordinates.
From: http://www.virtualdrugdevelopment.com/ferkany.htm
|
 |
Roger Frechette
Roger Frechette, PhD, received his doctorate in chemistry in 1987 from Wesleyan university and completed a NIH Postdoctoral fellowship at Yale University in 1989. He is a co-founder of MaxThera, a biopharmaceutical company developing novel antibacterial therapeutics, and is serving as Vice President of Chemistry and R&D Operations. Previously, Dr. Frechette founded NEPAssociates, a drug discovery consultancy. Prior to this, Dr. Frechette held Drug Discovery leadership positions at Paratek Pharmaceuticals and at RiboGene. He began his pharmaceutical research career as a Medicinal Chemist at Johnson & Johnson's R.W. Johnson Pharmaceutical Research Institute.
|
 |
Terry Kenakin
Beginning his career as a synthetic chemist, Terry Kenakin received a Ph.D. in Pharmacology at the Unversity of Alberta, Edmonton Canada. After a post-doctoral Fellowship at University College London, U.K., he joined Burrough-Wellcome as an associate Scientist. From there he continued working in drug discovery at Glaxo Inc. and GlaxoWellcome. He presently is a principal research scientist at GlaxoSmithKline Research and Development laboratories at Research Triangle Park, N.C. USA.
Dr Kenakin has been involved in drug discovery for over 30 years. Currently he is engaged in studies aimed at the optimal design of drug activity assays systems as well as the discovery and testing of molecules to block the entry of HIV-1 for treatment of AIDS. He is a member of numerous editorial boards as well as co-editor in Chief of the Journal of Receptors and Signal Transduction and, as well as numerous articles, has written 8 books on Pharmacology.
|
 |
Dr. Paul McGonigle
Dr. Paul McGonigle is currently the Vice President for Scientific Affairs at PsychoGenics Inc., a behavioral neurobiology company, where his efforts are focused on the development and application of proprietary technologies to discover novel drugs for psychiatric and neurodegenerative disorders. Prior to joining PsychoGenics, he co-founded and served as the CEO of NeuroGenix Corp., a biopharmaceutical company established to use neurogenesis as the basis for the discovery of new treatments for CNS disorders. Before forming NeuroGenix, Dr. McGonigle was the Director of Psychiatric Disorder Research at Wyeth where he supervised all aspects of drug discovery related to psychiatric disorders and advanced several compounds to clinical trials. Prior to joining Wyeth, he was on the faculty of the Department of Pharmacology at the University of Pennsylvania where his research focused on neurotransmitter receptors involved in psychiatric and neurodegenerative disorders. Dr. McGonigle has served on a number of NIH advisory panels and is an adjunct Professor of Pharmacology at the University of Pennsylvania and Drexel University School of Medicine.
|
 |
Bruce Ruggeri
Dr. Ruggeri received his Ph.D. in biochemistry from the University of Pennsylvania and pursued a post-doctoral fellowship at the Fox Chase Cancer Center in Philadelphia. He served on the faculty of Hahnemann University for several years before joining Cephalon, Inc. where he is now Director of oncology research. His primary areas of interest lie in tumor molecular pathology, particularly the cell and molecular regulation of tumor angiogenesis and processes of malignant progression in solid tumors. He has expertise in systems tumor biology and in vivo pharmacology, particularly development and application of orthotopic models of human cancer in drug discovery. His current research involves study of small molecule molecular-targeted therapeutic agents, including angiogenesis inhibitors, modulators of DNA damage and repair, inhibitors of the proteasome; and small molecule tyrosine kinase inhibitors for application against a variety of solid and hematopoietic tumors and myeloproliferative disorders.
Dr. Ruggeri has authored 53 peer-reviewed publications, five book chapters, and four patents. In addition to his editorial role for Current Protocols in Pharmacology, he serves as a reviewer for several oncology-related publications and the New Jersey Commission for Cancer Research, and also serves on the Editorial Boards of the International Journal of Gastrointestinal Cancer and Biochemical Pharmacology.
|
